Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published online before print January 25, 2006, doi:10.1212/01.wnl.0000200778.65597.ae)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Polish Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000200778.65597.aev1
66/5/678    most recent
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Received July 7, 2005
Accepted October 10, 2005

IM interferon {beta}-1a delays definite multiple sclerosis 5 years after a first demyelinating event

CHAMPIONS Study Group

From the Multiple Sclerosis Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.


Abstract-- Background: The Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS) showed that IM interferon {beta}-1a (IFN{beta}-1a) significantly slows the rate of development of clinically definite multiple sclerosis (CDMS) over 2 years in high-risk patients who experience a first clinical demyelinating event. This report highlights the primary results of a 5-year, open-label extension of CHAMPS (the Controlled High Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance [CHAMPIONS Study]). Objective: To determine if the benefits of IFN{beta}-1a observed in CHAMPS are sustained for up to 5 years. Methods: CHAMPS patients at participating CHAMPIONS sites were enrolled in the study. All patients were offered, but not required to take, IFN{beta}-1a 30 µg IM once weekly for up to 5 years (from CHAMPS randomization). Patients who received placebo in CHAMPS were considered the delayed treatment (DT) group, and patients who received IFN{beta}-1a in CHAMPS were considered the immediate treatment (IT) group. The primary outcome measure was the rate of development of CDMS. Additional outcomes included disease state classification at 5 years, annualized relapse rates, disability level at 5 years (Expanded Disability Status Scale), and MRI measures at 5 years. Results: Fifty-three percent (203/383) of patients enrolled in CHAMPIONS (n = 100, IT group; n = 103, DT group) and 64% (32/50) of CHAMPS study sites participated in CHAMPIONS. The median time to initiation of IFN{beta}-1a therapy in the DT group was 29 months. The cumulative probability of development of CDMS was significantly lower in the IT group compared with the DT group (5-year incidence 36 ± 9 vs 49 ± 10%; p = 0.03). Multivariate analysis suggested that the only factors independently associated with an increased rate of development of CDMS were randomization to the DT group and younger age at onset of neurologic symptoms. Few patients in either group developed major disability within 5 years. Conclusions: These results support the use of IM interferon {beta}-1a after a first clinical demyelinating event and indicate that there may be modest beneficial effects of immediate treatment compared with delayed initiation of treatment.




This article has been cited by other articles:


Home page
 Mult SclerHome page
L.I. Iezzoni, L.H. Ngo, and R.P. Kinkel
Working-age persons with multiple sclerosis and access to disease-modifying medications
Multiple Sclerosis, January 1, 2008; 14(1): 112 - 122.
[Abstract] [PDF]

Home page
 NeurologyHome page
M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Neurology, October 9, 2007; 69(15): 1498 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. P. Ross
Treatment strategies across the multiple sclerosis lifespan
Neurology, June 12, 2007; 68(24_suppl_4): S1 - S2.
[Full Text] [PDF]

Home page
 NeurologyHome page
P. K. Coyle
Evidence-based medicine and clinical trials
Neurology, June 12, 2007; 68(24_suppl_4): S3 - S7.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. W. Thrower
Clinically isolated syndromes: Predicting and delaying multiple sclerosis
Neurology, June 12, 2007; 68(24_suppl_4): S12 - S15.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. S. Goodin, R. P. Kinkel, and C. Kollman
IM interferon {beta}-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
Neurology, September 26, 2006; 67(6): 1104 - 1105.
[Full Text] [PDF]

Home page
 BMJHome page
B. Padmanabhan
Role of MRI in diagnosing multiple sclerosis: early diagnosis using MRI and early treatment delays disease conversion.
BMJ, April 29, 2006; 332(7548): 1034 - 1035.
[Full Text]

Home page
 NEJMHome page
L. J. Balcer
Clinical practice. Optic neuritis.
N. Engl. J. Med., March 23, 2006; 354(12): 1273 - 1280.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

IM interferon ß-1a delays definite multiple sclerosis 5 years after a first demyelinating event
Douglas S Goodin
Neurology Online, 5 Jun 2006 [Full text]
Reply from the authors
Revere P Kinkel, et al.
Neurology Online, 5 Jun 2006 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by AAN Enterprises, Inc.